These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 10831180)

  • 1. Improvement by the insulin-sensitizing agent, troglitazone, of abnormal fibrinolysis in type 2 diabetes mellitus.
    Kato K; Yamada D; Midorikawa S; Sato W; Watanabe T
    Metabolism; 2000 May; 49(5):662-5. PubMed ID: 10831180
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of troglitazone on blood concentrations of plasminogen activator inhibitor 1 in patients with type 2 diabetes and in lean and obese normal subjects.
    Kruszynska YT; Yu JG; Olefsky JM; Sobel BE
    Diabetes; 2000 Apr; 49(4):633-9. PubMed ID: 10871202
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of troglitazone on fibrinolysis and activated coagulation in patients with non-insulin-dependent diabetes mellitus.
    Fonseca VA; Reynolds T; Hemphill D; Randolph C; Wall J; Valiquet TR; Graveline J; Fink LM
    J Diabetes Complications; 1998; 12(4):181-6. PubMed ID: 9647334
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential effects of metformin and troglitazone on cardiovascular risk factors in patients with type 2 diabetes.
    Chu NV; Kong AP; Kim DD; Armstrong D; Baxi S; Deutsch R; Caulfield M; Mudaliar SR; Reitz R; Henry RR; Reaven PD
    Diabetes Care; 2002 Mar; 25(3):542-9. PubMed ID: 11874944
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Further insight on the hypoglycemic and nonhypoglycemic effects of troglitazone 400 or 600 mg/d: effects on the very-low-density and high-density lipoprotein particle distribution.
    Gómez-Pérez FJ; Aguilar-Salinas CA; Vázquez-Chávez C; Fanghänel-Salmón G; Gallegos-Martínez J; Gómez-Diaz RA; Salinas-Orozco S; Chavira-López IJ; Sánchez-Reyes L; Torres-Acosta EM; Tamez R; López A; Guillén LE; Cesarman G
    Metabolism; 2002 Jan; 51(1):44-51. PubMed ID: 11782871
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Troglitazone improves defects in insulin action, insulin secretion, ovarian steroidogenesis, and fibrinolysis in women with polycystic ovary syndrome.
    Ehrmann DA; Schneider DJ; Sobel BE; Cavaghan MK; Imperial J; Rosenfield RL; Polonsky KS
    J Clin Endocrinol Metab; 1997 Jul; 82(7):2108-16. PubMed ID: 9215280
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum leptin level as an indicator to predict the clinical efficacy of troglitazone in patients with type 2 diabetes mellitus.
    Maruyama S; Yanagisawa K; Kanamuro R; Teno S; Iwamoto Y
    Diabetes Res Clin Pract; 2001 Sep; 53(3):161-4. PubMed ID: 11483231
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of troglitazone on insulin action and cardiovascular risk factors in patients with non-insulin-dependent diabetes.
    Sironi AM; Vichi S; Gastaldelli A; Pecori N; Anichini R; Foot E; Seghieri G; Ferrannini E
    Clin Pharmacol Ther; 1997 Aug; 62(2):194-202. PubMed ID: 9284856
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Troglitazone, an insulin action enhancer, improves metabolic control in NIDDM patients. Troglitazone Study Group.
    Kumar S; Boulton AJ; Beck-Nielsen H; Berthezene F; Muggeo M; Persson B; Spinas GA; Donoghue S; Lettis S; Stewart-Long P
    Diabetologia; 1996 Jun; 39(6):701-9. PubMed ID: 8781766
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of troglitazone: a new hypoglycemic agent in patients with NIDDM poorly controlled by diet therapy.
    Iwamoto Y; Kosaka K; Kuzuya T; Akanuma Y; Shigeta Y; Kaneko T
    Diabetes Care; 1996 Feb; 19(2):151-6. PubMed ID: 8718436
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Troglitazone reduces plasma levels of tumour necrosis factor-alpha in obese patients with type 2 diabetes.
    Katsuki A; Sumida Y; Murata K; Furuta M; Araki-Sasaki R; Tsuchihashi K; Hori Y; Yano Y; Gabazza EC; Adachi Y
    Diabetes Obes Metab; 2000 Jun; 2(3):189-91. PubMed ID: 11220554
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of troglitazone in insulin-treated patients with type II diabetes mellitus. Troglitazone and Exogenous Insulin Study Group.
    Schwartz S; Raskin P; Fonseca V; Graveline JF
    N Engl J Med; 1998 Mar; 338(13):861-6. PubMed ID: 9516220
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Troglitazone use in insulin-treated type 2 diabetic patients. The Troglitazone Insulin Study Group.
    Buse JB; Gumbiner B; Mathias NP; Nelson DM; Faja BW; Whitcomb RW
    Diabetes Care; 1998 Sep; 21(9):1455-61. PubMed ID: 9727891
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of troglitazone in type 2 diabetes mellitus.
    Gorson DM
    N Engl J Med; 1998 Aug; 339(6):406. PubMed ID: 9696655
    [No Abstract]   [Full Text] [Related]  

  • 15. Effect of troglitazone in type 2 diabetes mellitus.
    Rusk MH
    N Engl J Med; 1998 Aug; 339(6):406. PubMed ID: 9696656
    [No Abstract]   [Full Text] [Related]  

  • 16. A comparison of troglitazone and metformin on insulin requirements in euglycemic intensively insulin-treated type 2 diabetic patients.
    Yu JG; Kruszynska YT; Mulford MI; Olefsky JM
    Diabetes; 1999 Dec; 48(12):2414-21. PubMed ID: 10580431
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Troglitazone monotherapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, controlled study. The Troglitazone Study Group.
    Fonseca VA; Valiquett TR; Huang SM; Ghazzi MN; Whitcomb RW
    J Clin Endocrinol Metab; 1998 Sep; 83(9):3169-76. PubMed ID: 9745421
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of a thiazolidinedione drug, troglitazone, on glycemia in patients with type 2 diabetes mellitus poorly controlled with sulfonylurea and metformin. A multicenter, randomized, double-blind, placebo-controlled trial.
    Yale JF; Valiquett TR; Ghazzi MN; Owens-Grillo JK; Whitcomb RW; Foyt HL
    Ann Intern Med; 2001 May; 134(9 Pt 1):737-45. PubMed ID: 11329231
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Deterioration of glycemic control after long-term treatment with troglitazone in nonobese type 2 diabetic patients.
    Murase Y; Wakasugi T; Yagi K; Mabuchi H
    Diabetes Care; 2000 Jan; 23(1):131-2. PubMed ID: 10857989
    [No Abstract]   [Full Text] [Related]  

  • 20. Troglitazone decreases serum uric acid concentrations in type II diabetic patients and non-diabetics.
    Iwatani M; Wasada T; Katsumori K; Watanabe-Takahashi C; Kamatani N; Iwamoto Y
    Diabetologia; 2000 Jun; 43(6):814-5. PubMed ID: 10907128
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.